Japanese Firm Luring Investors With Nobel-Winning Technology

Retina Institute Japan K.K., which is employing Nobel Prize-winning stem-cell technology to treat eye diseases, plans to sell a stake in itself to a group of Japanese companies next month ahead of a possible initial public offering in five years.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.